Funding profile · Radiology AI, Latin America

Eden

A Mexico City radiology platform, legally organized in Delaware as Higia, Inc. Three Form D notices on file show $22,428,584 sold to investors between 2020 and 2024, against a $22 million Series A the company announced in October 2025 that has not yet shown up as a new filing.

$22MSeries A announced October 2025, company reported
$22.43MTotal sold across 3 Form D filings, 2020 to 2024, public record
$9.5MOffered in the most recent Form D, of which $7.89M sold
3Form D notices on file under Higia, Inc., 2020 to 2024

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Summer 2018 Y Combinator, as Higia Technologies Not disclosed Y Combinator; angels including Ashton Kutcher, per Dealroom Aggregator
By Apr 2020 Early round $9,133,896 sold of $16,133,896 offered 34 investors, about $268,600 average Form D
Jan 2022 Round reported near $7M by press aggregators (Jun 2022) $5,403,130 sold, fully subscribed against that offering 7 investors, about $771,900 average Form D
Jul 2024 Round announced as “$10M in additional funding,” led by Sierra Ventures $7,891,558 sold of $9,500,000 offered, per the filing 3 months earlier 6 investors, about $1,315,300 average; Sierra Ventures partner Mark Fernandes added as director Form D + release
Oct 2025 Series A, led by Sierra Ventures, with Liquid 2 Ventures and Daniel Servitje $22M announced No Form D found for this round as of Sep 25, 2026 Company release

What the filings show

Higia, Inc. · Form D · filed May 5, 2020

First sale
Apr 21, 2020
Offered
$16,133,896 equity
Sold
$9,133,896 · $7,000,000 remaining
Investors
34 · average about $268,600
Exemption
Rule 506(b)
Related persons
Julian Rios (executive officer, director); Jose Antonio Torres (director); Nicolas Berman (director)
Filing
SEC EDGAR, CIK 0001811218

Higia, Inc. · Form D · filed May 9, 2023

First sale
Jan 12, 2022
Offered
$5,403,130, options to acquire securities
Sold
$5,403,130 · fully sold
Investors
7 · average about $771,900
Exemption
Rule 506(b)
Related persons
Julian Rios Cantu (director, promoter); Jose Antonio Torres Gonzalez (director); Nicholas Berman (director)
Filing
SEC EDGAR, CIK 0001811218

Higia, Inc. · Form D · filed Apr 30, 2024

First sale
Apr 16, 2024
Offered
$9,500,000 equity
Sold
$7,891,558 · $1,608,442 remaining
Investors
6 · average about $1,315,300; minimum investment $50,000
Exemption
Rule 506(b)
Related persons
Julian Rios Cantu (director, promoter); Raymundo Gonzalez Leal (director); Nicholas Berman (director); Mark Fernandes (director)
Filing
SEC EDGAR, CIK 0001811218

Reading the filings

  1. The filer is not “Eden.”All three notices are filed under Higia, Inc., the Delaware corporation formed for the original Eva breast cancer bra. The brand changed to Eden around 2021 to 2022; the SEC filer name never did.
  2. The 2022 round fell short of what was reported.Press aggregators put the round announced around June 2022 near $7 million. The Form D covering that period, filed in May 2023, well past the usual 15 day window, shows $5,403,130 sold to 7 investors, fully subscribed against that specific offering. The gap could reflect a different accounting of the round, additional unfiled capital, or a rounded press figure.
  3. The April 2024 filing landed before the announcement.First sale was April 16, 2024 and the notice was filed April 30, 2024. The public release crediting Sierra Ventures with a “$10M” round did not appear until July 17, 2024, about eleven weeks later. Sierra Ventures managing partner Mark Fernandes appears as a new director on that same filing, tying the paperwork to the announced lead investor.
  4. Average check size has grown with each filing.About $268,600 per investor in 2020, rising to about $771,900 in the 2022 filing and about $1,315,300 in the 2024 filing. Fewer, larger checks track a company moving from an angel heavy cap table toward institutional venture rounds.
  5. No Form D has appeared for the announced $22 million Series A.Eden and Sierra Ventures both described the October 2025 round as $22 million, but a full text search of SEC EDGAR under Higia, Inc. as of September 25, 2026 turns up no filing dated after April 2024. If the round has priced and begun closing, a notice would normally be due within 15 days of the first sale under Regulation D.
  6. The board has changed with the money.Directors named across the three filings are Julian Rios Cantu in all three; Jose Antonio Torres or Torres Gonzalez in the first two; Nicholas Berman in all three; and, starting only in 2024, Raymundo Gonzalez Leal and Sierra Ventures’ Mark Fernandes.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k) or PMA record and no public COFEPRIS device registration found for Eden’s AI reporting tools as of Sep 25, 2026. Not found
Customers named Grupo Diagnostico PROA, Laboratorios del Chopo, Grupo Santa Maria, Lapi Laboratorio, Imagenologia Christus Muguerza, and the health secretariats of Chiapas and Chihuahua, per a July 2024 release. Not independently confirmed by those organizations. Company-stated
Scale claims Self-reported footprint grew from about 100 institutions (Jan 2022) to 1,500 across 17 countries (Jul 2024) to 2,200 across 18 countries (Oct 2025) to 2,800 plus across 20 countries on the current company site. Company-stated
Public sector reach Eden told Mexico Business News in October 2023 that it had impacted over 250,000 patients in the public sector across several states including Chihuahua. Interview
Radiologist adoption Eden and Sierra Ventures both state 75 percent of radiologists in Mexico use the platform, first published July 2024. No independent survey found. Company and investor stated

What to watch

  • A Form D for the $22 million Series A announced in October 2025, or public confirmation the round closed without one.
  • An amended or late filing that reconciles the 2022 round’s reported and filed amounts.
  • Named customers confirmed independently of company releases.
  • Any COFEPRIS or FDA record for Eden’s AI reporting tools.

The Eden story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • H1: Shared investor: Liquid 2. A New York company that keeps a profile of roughly every doctor on earth and sells it to pharma, health insurers and now AI developers
  • Lively: Shared investor: Liquid 2. A San Francisco company that rebuilt the health savings account around the person who has to use one, then sold that machinery to banks and employers
  • BloomAPI: Shared investor: Liquid 2. A Y Combinator company that set out to end the medical records fax, then quietly turned into a HIPAA texting app
  • Scanbase: Shared investor: Liquid 2. An API that turns a phone photo of a rapid diagnostic test into a result, sold to the companies that make and ship the tests

Sources

  1. Public recordForm D, Higia, Inc.SEC EDGAR · filed May 5, 2020
  2. Public recordForm D, Higia, Inc.SEC EDGAR · filed May 9, 2023
  3. Public recordForm D, Higia, Inc.SEC EDGAR · filed Apr 30, 2024
  4. IndependentMexican platform advances digital diagnostics in Latin AmericaFinancial Times, Angelica Mari · Jan 31, 2022
  5. IndependentCloud-Based Platform Empowers RadiologistsMexico Business News · Oct 12, 2023
  6. IndependentOur Early-Stage Investment in EdenSierra Ventures, Mark Fernandes · Jul 17, 2024
  7. IndependentEden raises $22M Series ALatamList, Araceli Dominguez · Oct 10, 2025
  8. IndependentEden secures $10M to invest in AI for clinical diagnosticsLatamList · Jul 16, 2024
  9. IndependentEden – 2026 Company Profile & TeamTracxn · accessed Sep 25, 2026
  10. IndependentEden company information, funding and investorsDealroom.co · accessed Sep 25, 2026
  11. CompanyEden Secures $10M to Transform Radiology in Latin America with AIEuropean Business Magazine, ACCESSWIRE release · Jul 17, 2024
  12. CompanyEden Secures $10M to Transform Radiology in Latin America with AITennessee Daily, ACCESS Newswire release · Jul 17, 2024

Compiled from SEC public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Eden. This page is not an offer to sell or a recommendation to buy any security.